000			01890 a2200565 4500
005			20250516035217.0
264		0	_c20120203
008			201202s 0 0 ger d
022			_a1433-0563
024	7		_a10.1007/s00120-011-2553-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aSiebels, M
245	0	0	_a[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. _h[electronic resource]
260			_bDer Urologe. Ausg. A _cSep 2011
300			_a1110-7 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aData Collection
650	0	4	_aDisease Progression
650	0	4	_aDrug Delivery Systems
650	0	4	_aEverolimus
650	0	4	_aFemale
650	0	4	_aGermany
650	0	4	_aHumans
650	0	4	_aIndoles _xadministration & dosage
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aPractice Patterns, Physicians'
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aPyrroles _xadministration & dosage
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
700	1		_aHegele, A
700	1		_aVarga, Z
700	1		_aOberneder, R
700	1		_aDoehn, C
700	1		_aHeinzer, H
773	0		_tDer Urologe. Ausg. A _gvol. 50 _gno. 9 _gp. 1110-7
856	4	0	_uhttps://doi.org/10.1007/s00120-011-2553-3 _zAvailable from publisher's website
999			_c20823061 _d20823061